Bayer acquires Merck's consumer care business for $14.2B

05/7/2014 | Reuters · American City Business Journals

Merck agreed to sell its consumer care unit to Germany's Bayer for $14.2 billion as part of efforts to focus on its branded prescription drug business. The acquisition, which is expected to be finalized in the second half of this year, will give Bayer rights to Merck's over-the-counter products, including allergy drug Claritin and Afrin nasal spray. The deal will also make Bayer the world's second-largest consumer health care firm. "This acquisition marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business," Bayer CEO Marijn Dekkers said.

View Full Article in:

Reuters · American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY